The upcoming antitrust trial over Cephalon’s alleged reverse-payment settlements with generic drug companies needs to be bifurcated at the liability phase, a federal judge has ruled.

U.S. District Court Judge Mitchell Goldberg of the Eastern District of Pennsylvania determined that the liability portion of the trial will need to be split into violation and causation phases in order to allow jurors to hear key evidence about the validity of the pharmaceutical patent underlying the case without prejudicing the defendants.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]